{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-102805","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.517788+00:00","generated_at":"2026-05-31T06:39:45.676624+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study","bullets":["All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.","FVIII levels consistent from 3-6 month to 9-12 month time points; no significant decline.","Liver biopsy showed gene integration in forward orientation at 0.7% to 2.9%.","Treatment well tolerated with only moderate transient liver transaminase elevations.","Program on track for IND filing in 2026; company declared MGX-001 as development candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-102805","json":"https://secwatch.observer/filing/0000950170-24-102805.json","markdown":"https://secwatch.observer/filing/0000950170-24-102805.md","text":"https://secwatch.observer/filing/0000950170-24-102805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024102805/0000950170-24-102805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024102805/mgx-20240903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:39:45.676624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}